pharmaphorum January 18, 2024
Medtech company DermaSensor has claimed FDA approval for a handheld device, powered by artificial intelligence (AI), that can be used to detect skin cancer at the point of care.
The eponymous device, the first FDA-cleared skin cancer device for primary care use, combines a light emission technology called elastic scattering spectroscopy (ESS) that measures the physical properties of tissue with an AI algorithm to interpret the data.
It can deliver a result within seconds when the optical probe on the device is applied to a suspect lesion on the skin, making it suitable for use by primary care physicians, according to DermaSensor. It is viewed as an addition to the visual assessment by a doctor that is the current standard...
Today's Sponsors
Today's Sponsor